Hansa Biopharma AB (publ) (HNSA.ST)
SEK 20.62
(-4.98%)
SEK 20.62
(-4.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 859.44 Million SEK | 24.27% |
| 2022 | 692.16 Million SEK | 24.04% |
| 2021 | 558.03 Million SEK | 29.72% |
| 2020 | 430.17 Million SEK | 19.46% |
| 2019 | 360.09 Million SEK | 47.45% |
| 2018 | 244.22 Million SEK | 36.18% |
| 2017 | 179.34 Million SEK | 58.01% |
| 2016 | 113.49 Million SEK | 59.91% |
| 2015 | 70.97 Million SEK | 143.24% |
| 2014 | 29.18 Million SEK | 53.19% |
| 2013 | 19.04 Million SEK | -13.07% |
| 2012 | 21.91 Million SEK | -20.2% |
| 2011 | 27.46 Million SEK | 12.36% |
| 2010 | 24.44 Million SEK | 30.53% |
| 2009 | 18.72 Million SEK | 16.96% |
| 2008 | 16 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 175.48 Million SEK | -7.99% |
| 2024 Q3 | 154.21 Million SEK | -12.12% |
| 2024 Q1 | 190.71 Million SEK | -10.98% |
| 2023 Q1 | 196.89 Million SEK | 23.05% |
| 2023 Q3 | 208.33 Million SEK | -15.44% |
| 2023 FY | 860.13 Million SEK | 24.27% |
| 2023 Q4 | 214.24 Million SEK | 2.83% |
| 2023 Q2 | 246.38 Million SEK | 25.14% |
| 2022 Q2 | 189.15 Million SEK | 22.77% |
| 2022 Q1 | 154.06 Million SEK | -7.82% |
| 2022 FY | 692.16 Million SEK | 24.04% |
| 2022 Q4 | 160 Million SEK | -15.31% |
| 2022 Q3 | 188.94 Million SEK | -0.11% |
| 2021 Q2 | 134.55 Million SEK | 21.28% |
| 2021 Q1 | 110.95 Million SEK | -1.04% |
| 2021 FY | 558.03 Million SEK | 29.72% |
| 2021 Q3 | 145.39 Million SEK | 8.05% |
| 2021 Q4 | 167.13 Million SEK | 14.95% |
| 2020 FY | 430.17 Million SEK | 19.46% |
| 2020 Q1 | 91.81 Million SEK | -15.83% |
| 2020 Q2 | 102.33 Million SEK | 11.46% |
| 2020 Q3 | 123.92 Million SEK | 21.1% |
| 2020 Q4 | 112.11 Million SEK | -9.53% |
| 2019 Q4 | 109.08 Million SEK | 16.5% |
| 2019 Q3 | 93.63 Million SEK | 11.24% |
| 2019 Q2 | 84.17 Million SEK | 15.0% |
| 2019 Q1 | 73.19 Million SEK | -4.32% |
| 2019 FY | 360.09 Million SEK | 47.45% |
| 2018 FY | 244.22 Million SEK | 36.18% |
| 2018 Q1 | 47.16 Million SEK | -5.53% |
| 2018 Q4 | 76.5 Million SEK | 25.55% |
| 2018 Q3 | 60.93 Million SEK | 2.21% |
| 2018 Q2 | 59.61 Million SEK | 26.41% |
| 2017 Q3 | 38.05 Million SEK | -16.43% |
| 2017 Q4 | 49.91 Million SEK | 31.16% |
| 2017 FY | 179.34 Million SEK | 58.01% |
| 2017 Q1 | 45.82 Million SEK | 32.98% |
| 2017 Q2 | 45.54 Million SEK | -0.62% |
| 2016 Q1 | 20.43 Million SEK | 7.77% |
| 2016 FY | 113.49 Million SEK | 59.91% |
| 2016 Q3 | 27.44 Million SEK | -11.94% |
| 2016 Q4 | 34.46 Million SEK | 25.57% |
| 2016 Q2 | 31.16 Million SEK | 52.5% |
| 2015 FY | 70.97 Million SEK | 143.24% |
| 2015 Q1 | 14.53 Million SEK | 25.66% |
| 2015 Q3 | 14.45 Million SEK | -37.22% |
| 2015 Q2 | 23.02 Million SEK | 58.4% |
| 2015 Q4 | 18.96 Million SEK | 31.16% |
| 2014 Q3 | 5.42 Million SEK | 4.59% |
| 2014 Q4 | 11.56 Million SEK | 113.39% |
| 2014 Q1 | 7.35 Million SEK | 3.65% |
| 2014 Q2 | 5.18 Million SEK | -29.51% |
| 2014 FY | 29.18 Million SEK | 53.19% |
| 2013 Q3 | 7.09 Million SEK | 192.54% |
| 2013 Q2 | 2.42 Million SEK | 0.0% |
| 2013 Q4 | 7.09 Million SEK | 0.0% |
| 2013 Q1 | 2.42 Million SEK | -70.84% |
| 2013 FY | 19.04 Million SEK | -13.07% |
| 2012 Q4 | 8.31 Million SEK | 0.0% |
| 2012 FY | 21.91 Million SEK | -20.2% |
| 2011 FY | 27.46 Million SEK | 12.36% |
| 2010 FY | 24.44 Million SEK | 30.53% |
| 2009 FY | 18.72 Million SEK | 16.96% |
| 2008 FY | 16 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -2124.127% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | -167.319% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | -140.322% |
| Xintela AB (publ) | 57.31 Million SEK | -1399.489% |
| Active Biotech AB (publ) | 44.8 Million SEK | -1818.023% |
| Amniotics AB (publ) | 29.07 Million SEK | -2856.271% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -5765.332% |
| BioArctic AB (publ) | 89.62 Million SEK | -858.915% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 43.242% |
| Camurus AB (publ) | 1.05 Billion SEK | 18.894% |
| Cantargia AB (publ) | 290.01 Million SEK | -196.344% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -3825.312% |
| CombiGene AB (publ) | 44.14 Million SEK | -1846.912% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -501.067% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -2934.091% |
| Genovis AB (publ.) | 88.19 Million SEK | -874.463% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -646.871% |
| Mendus AB (publ) | 129.13 Million SEK | -565.531% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -11725.083% |
| Intervacc AB (publ) | 79.78 Million SEK | -977.204% |
| Kancera AB (publ) | 63.07 Million SEK | -1262.536% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -15472.513% |
| LIDDS AB (publ) | 27.75 Million SEK | -2996.883% |
| Lipum AB (publ) | 37.3 Million SEK | -2203.715% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -11747.905% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -532.355% |
| NextCell Pharma AB | -576.01 Thousand SEK | 149304.627% |
| OncoZenge AB (publ) | 15.9 Million SEK | -5303.628% |
| Saniona AB (publ) | 1.07 Million SEK | -79700.093% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -372.915% |
| Ziccum AB (publ) | 27.87 Million SEK | -2982.886% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -5140.211% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | -179.868% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -1915.967% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -4760.301% |
| Corline Biomedical AB | 30.16 Million SEK | -2748.87% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -1381.014% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -933.374% |
| Aptahem AB (publ) | 10.01 Million SEK | -8483.36% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -538.074% |
| Fluicell AB (publ) | 28.61 Million SEK | -2903.274% |
| Biovica International AB (publ) | 133.72 Million SEK | -542.712% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -4242.835% |
| AcouSort AB (publ) | 25.87 Million SEK | -3221.406% |
| Abliva AB (publ) | 27.86 Million SEK | -2984.214% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -344.159% |
| 2cureX AB (publ) | 36.51 Million SEK | -2253.489% |
| I-Tech AB | 40.14 Million SEK | -2040.697% |
| Cyxone AB (publ) | 28.21 Million SEK | -2946.172% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -685.83% |
| Biosergen AB | 26.8 Million SEK | -3105.815% |
| Nanologica AB (publ) | 69.88 Million SEK | -1129.767% |
| SynAct Pharma AB | 224.49 Million SEK | -282.834% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -1845.507% |
| BioInvent International AB (publ) | 441.4 Million SEK | -94.708% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -3487.866% |
| Alzinova AB (publ) | 36.39 Million SEK | -2261.378% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -196.621% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -10839.633% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -674.877% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -5746.578% |